BioLife Solutions, Inc. · NASDAQ:BLFS

BioLife Solutions — OneMed Forum (January 2015)

46 slides from BioLife Solutions's conference presentation, January 2015

  1. Slide 1: Investor Presentation January 2015

    NASDAQ:BLFS Investor InvestorPresentation Presentation January January2015 2015

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the anticipated business and operations of our new joint venture, the potential utility of and market for its planned products and services, its expected finances, potent

  3. Slide 3: Best-in-class life sciences tools provider

    NASDAQ: BLFS  Best-in-class life  IP embedded in 175 sciences tools regenerative medicine provider clinical trials  25% annual core  $10M cash, no debt products revenue at 12/31/14 growth 3

  4. Slide 4: Biopreservation

    BIOPRESERVATION BIOLOGISTICS 4

  5. Slide 5: Biopreservation

    Biopreservation The scientific methods and tools used to effectively preserve biologic materials outside the body by ensuring …  survival  recovery  functional performance … when used in clinical infusion, injection, or transplantation in patients 5

  6. Slide 6: Ex-Vivo Survival of Biologics

    Ex-Vivo Survival of Biologics 6

  7. Slide 7: Biopreservation in Regenerative Medicine

    BIOPRESERVATION IN REGENERATIVE MEDICINE Source Preservation Temperature Material Media Controlled Container Patient Cell Factory Preservation Media Temperature Manufactured Controlled Products Container BIOLOGISTICS 7

  8. Slide 8: Complementary Biopreservation Tools Platforms

    Complementary Biopreservation Tools Platforms Each is Critical to our Customers’ Clinical and Commercial Success Biopreservation Smart Shipping Media for Cells Containers 8

  9. Slide 9: Biopreservation Media Products

    BIOPRESERVATION MEDIA PRODUCTS 9

  10. Slide 10: Clinical Grade Biopreservation Storage Media

    Clinical Grade Biopreservation Storage Media Engineered to improve yield and extend shelf-life of biologics Better cell yield More precious cells saved, reduced variable costs Longer shelf-life of clinical cells Lower customer MFG CAPEX requirements 10

  11. Slide 11: HypoThermosol FRS

    HYPOTHERMIC STORAGE AND SHIPPING MEDIA HypoThermosol FRS® Decreases free radical accumulation in cold storage process Balances intracellular state at low temperatures Improved yield and extended stability of cells and tissues 11

  12. Slide 12: CryoStor

    CRYOPRESERVATION / FREEZE MEDIA CryoStor® Improved yield of cells and tissues Mitigates molecular cell stress during freezing and thawing 12

  13. Slide 13: Better Cell Yield

    BETTER CELL YIELD Increased cell survival; reduced costs Condition of cells after 5 days of cold storage Traditional Home Brew Media BioLife Storage Media 13

  14. Slide 14: Enabling Manufacturing Cost Reductions for Our Customers

    Enabling Manufacturing Cost Reductions for Our Customers Increased yield leads to … … decreased cost Source Material Manufactured Cell Products LESS LESS Required Required Yield Yield Cost Cost 14

  15. Slide 15: Limited Shelf-Life

    Increased CAPEX requirements for LIMITED SHELF-LIFE manufacturers of cellular therapeutics Distribution range limited by short shelf-life - multiple production facilities required 15

  16. Slide 16: Longer Shelf Life, Reduced CAPEX Requirements

    LONGER SHELF LIFE Reduced CAPEX Requirements BioLife Solutions Preservation Media Performance Extends Shelf Life to Support Worldwide Distribution of Cellular Therapeutics 16

  17. Slide 17: Demand for Biopreservation Media

    DEMAND FOR BIOPRESERVATION MEDIA (MILLIONS) $900 $820.0 $700 Major growth expected from Regenerative $500 Medicine segment $345.0 $300 $100 2004 2019 Source: Biopreservation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 (Transparency Market Research, April,

  18. Slide 18: Biologistics

    BIOPRESERVATION BIOLOGISTICS 18

  19. Slide 19: Biologistics

    Biologistics The processes, tools, and data used to manage and monitor the movement of biologic materials across time and space to ensure…  secure, on-time arrive at the destination  maintenance within validated temperature  patient dosing within the validated stability profile 19

  20. Slide 20: Biologistics Drivers

    Biologistics Drivers • All vaccines and 70% of biologics are temperature sensitive • Cold chain yield losses due to improper storage are significant – up to 3% annually in pharma • In the developing regenerative medicine market, clinical therapies include simple to complex, sensitive cells and tissu

  21. Slide 21: Current Paradigm

    Current Paradigm • Billions spent annually on cold chain logistics of drugs, vaccines, cells, tissues, and organs (iMARC Group 12/2013) • Limited use of real-time temperature monitoring and reporting during shipment (“validate then assume” approach) • Significant opportunities exist to reduce cost a

  22. Slide 22: Demand for Biopreservation Equipment: Cold Chain Shippers and Instruments

    DEMAND FOR BIOPRESERVATION EQUIPMENT COLD CHAIN SHIPPERS AND INSTRUMENTS (BILLIONS) 2013 Worldwide Cold Chain Spend: $7.5 Billion Transportation Specialized Packaging $2,600,000,000 $4,900,000,000 Source: IMS Health, Evaluate Pharma 22

  23. Slide 23: Demand for Biopreservation Equipment: Cold Chain Shippers and Instruments

    DEMAND FOR BIOPRESERVATION EQUIPMENT COLD CHAIN SHIPPERS AND INSTRUMENTS (BILLIONS) $6 $5.1 $5 $4 $3.2 $3 $2 $1 $0 2013 2018 Source: iMarc Group, December 2013 23

  24. Slide 24: Customer Risks

    Customer Risks • Clinical: • Administering a thermally sensitive biologic dose that was exposed to unknown temperature excursions or opened during transit • Economic: • Cost of scrapping biologic source material or manufactured cell product due to: • Identified temperature excursion • Unable to loca

  25. Slide 25: Competition – Foam Coolers

    COMPETITION – FOAM COOLERS • Expanded polystyrene foam • Extruded polystyrene foam • Minimal performance • Technology essentially unchanged for over 25 years • Single use 25

  26. Slide 26: Competition – Vacuum Panel Shipper

    COMPETITION – VACUUM PANEL SHIPPER • Very large footprint • Expensive to ship • Heavy • Complicated assembly • Refrigerants must be preconditioned to multiple temperature ranges before use 26

  27. Slide 27: Biologistics Products & Services

    BIOLOGISTICS PRODUCTS & SERVICES 27

  28. Slide 28: EVO Smart Container

    EVO™ - SMART CONTAINER • Reusable • Simple packout process • Payload cavity sized for typical regenerative medicine final product packaging 28

  29. Slide 29: Biologistex CCM: Breakthrough Disruptive Technology

    Biologistex CCMSM: Breakthrough Disruptive Technology • Reusable, super insulating shipping container • Smart box – integrated cell phone and payload monitoring electronics • Cloud-hosted biologistics management app • Innovation driving best quality practices in logistics of regenerative medicines •

  30. Slide 30: Web App – SaaS Business Model

    Web App – SaaS Business Model 30

  31. Slide 31: SaaS Business Model

    SaaS Business Model Potential to Build a Base of Thousands of Shippers Deployed Throughout the World – Each Generating Subscription Revenue for Rental and Data Access 31

  32. Slide 32: Contract Manufacturing Services

    CONTRACT MANUFACTURING SERVICES • Utilizing excess production capacity • Niche provider of aseptic media formulation, fill, and finish services • New multiyear agreement with Somahlution, LLC 32

  33. Slide 33: Our Markets

    OUR MARKETS II BioLire SOLUTIONS’ BIOPRESERVATION TOOLS FOR CELLS, TISSUES, AND ORGANS

  34. Slide 34: We Serve Traditional and Emerging Markets

    WE SERVE TRADITIONAL AND EMERGING MARKETS Traditional Markets Emerging Market • Stable, growing (in $M) • Explosive growth (in $B) • Well-established relationships • BioLife products embedded in 175 trials • Reliable income streams Drug Regenerative Biobanking Discovery Medicine BIOLOGISTICS 34

  35. Slide 35: Biobanking

    BIOBANKING • Umbilical cord blood banks • Adult stem cell banks • Tissue banks • Biorepositories • Hair transplant physicians 35

  36. Slide 36: Drug Discovery

    DRUG DISCOVERY • Pharmaceutical companies • Cell suppliers • Toxicity testing labs 36

  37. Slide 37: Regenerative Medicine

    REGENERATIVE MEDICINE • Commercial cell therapy and tissue engineering companies • Hospital-based stem cell transplant centers • University-based clinical research labs 37

  38. Slide 38: Regenerative Medicine Customer Base

    REGENERATIVE MEDICINE CUSTOMER BASE Stroke ALD & MS ALS UTD* AMD AMI CHF & DCM Liver Disorders GVHD Spinal Disorders HIV Lymphoma Melanoma AML Autoimmune Incontinence UTD* Cancer Wound healing Joint Repair CLI Cancer * UNABLE TO DISCLOSE 38

  39. Slide 39: Products Used in 175 Clinical Trials

    Products Used in 175 Clinical Trials Indication Pre-Clinical Phase I Phase II Phase III Solid Tumors 4 17 36 5 Hematologic Malignancies 8 8 11 2 Heart Disease 1 2 8 2 Stroke 0 0 4 0 Joint Disease 4 1 1 2 Vision Loss 1 1 0 0 Immune Disorders 8 9 9 2 All Others 7 9 8 8 Totals 33 47 77 21 39

  40. Slide 40: BioLife Products Embedded in Cellular Immunotherapy

    BioLife Products Embedded in Cellular Immunotherapy DISCLOSED CUSTOMERS CONFIDENTIAL Nearly all other high- profile, development stage immunotherapy companies; unable to disclose at this time 40

  41. Slide 41: Global Regenerative Medicine Market Revenue

    GLOBAL REGENERATIVE MEDICINE MARKET REVENUE (USD BILLIONS) 25 $23.3 20 15 10 5 $3.6 0 2012 2024 Source: visiongain – December 2013 41

  42. Slide 42: Investment Opportunity

    INVESTMENT OPPORTUNITY 42

  43. Slide 43: Well Positioned for Future Growth

    Well Positioned for Future Growth • Over 500 existing customers • Growing adoption in expanding biobanking and drug discovery markets • Embedded in rapidly emerging regenerative medicine market with products incorporated in over 175 clinical trials; 21 in Phase III • New biologistex SaaS business po

  44. Slide 44: Investment Fundamentals

    INVESTMENT FUNDAMENTALS December 31, 2014 Cash and Investments $10M Total Debt $0.00 Total Stockholder Equity $12.7M Shares Outstanding 12M 3/25/14 – issued 3.6M shares at $4.30 Options 1.4M most in the money Warrants 7.4M most at $4.75 – debt conversion/equity raise Average Volume ~25,000 shares Ma

  45. Slide 45: Continued adoption of core products

     Continued adoption of core products – creates tremendous upside as customers gain approvals to market regenerative medicine products and therapies  biologistex CCMsm cold chain management service – complementary to core business  Niche, profitable CMO business 45

  46. Slide 46: BioLife Solutions, Inc.

    NASDAQ:BLFS BioLife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 For additional questions or comments, please contact: Michael Rice | President and CEO mrice@BioLifeSolutions.com | (425) 686-6003 Daphne Taylor | CFO, VP - Finance & Administration dtaylor@BioLifeSolutions.com

BioLife Solutions — OneMed Forum (January 2015) on 6ix